Detailed narrative
Medicare Advantage Product & Experience
Humana's individual MA membership decline was less than expected, partly due to 'bounce back' members returning during OEP/ROI, who typically have better year-one economics. The company is enhancing member experience through new prior authorization actions, going beyond AHIP commitments, and a partnership with Epic to integrate health plan information into MyChart for increased cost transparency, aiming to make prior authorization invisible to members.
Clinical Excellence and Stars Performance
The Stars litigation was dismissed on administrative grounds and has been refiled, with management emphasizing continued operational progress in closing care gaps and driving quality for BY '27 and BY '28. The company will enter a quiet period for BY '27 Stars data until final CMS results are released in October, but expects underlying metric performance to show improvement.
Operational Transformation and Efficiency
Humana is undergoing a multi-year transformation to enable scalable growth and drive operating leverage, incorporating near-term tactical cost programs and longer-term automation and technology efforts. This includes an early retirement program, plans to expand outsourcing of shared services functions, and evolving employee benefits to align with industry standards, all aimed at creating a more nimble, technology-enabled organization.
Medicaid Expansion and Strategic Positioning
Strategic expansion of Medicaid continues, with 10 active states and 3 more awarded and pending, including a new Illinois contract. Humana's Medicaid footprint is largely in non-expansion states and skewed towards the LTSS population, which management believes makes it less impacted by the 'Big Beautiful Bill' compared to Medicaid broadly. Performance is currently in line with expectations, and the company remains committed to its margin progression assumptions.
CenterWell Pharmacy Outperformance
CenterWell Pharmacy delivered outperformance year-to-date, driven by higher direct-to-consumer volume and favorability in Specialty Pharmacy. This includes higher volumes and a more favorable drug mix than expected, boosted by strategic partnerships with pharma companies and increased access to multiple limited distribution drugs, which were previously inaccessible.
Capital Allocation and Balance Sheet Management
Humana completed approximately $100 million in share repurchases in Q2 to offset dilution and bought back approximately $200 million of debt due in 2027. The company maintains a prudent near-term capital deployment approach, focusing on maximizing shareholder value through share buybacks to offset dilution, growing dividends in line with earnings recovery, and long-term accretive M&A.